CEL-SCI Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CVM NYSE American 2836 cel-sci.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CEL-SCI Corporation

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Aug 4th, 2026 6:00 am
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Jul 30th, 2026 6:31 am
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer - Jul 13th, 2026 6:00 am
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Jun 15th, 2026 5:12 am
Cel-Sci: Fiscal Q1 Earnings Snapshot - Feb 17th, 2026 3:14 pm
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 - Oct 20th, 2025 7:00 am
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference - Oct 10th, 2025 6:00 am
Cel-Sci: Fiscal Q3 Earnings Snapshot - Aug 14th, 2025 7:37 am